Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01910545 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of OTS167 in Patients With Solid Tumors
A Phase 1 study, sponsored by OncoTherapy Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01910545 is a Phase 1 study that has completed, run by OncoTherapy Science. The registered enrollment target is 32 participants.
The verdict
NCT01910545, a Phase 1 study, has completed, sponsored by OncoTherapy Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.
Interventions
- DRUG OTS167IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-08-23 |
| Est. Completion | 2016-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01910545
The ClinicalTrials.gov registry entry for NCT01910545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoTherapy Science, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTS167IV is the first listed.
NCT01910545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01910545 about?
NCT01910545 is a clinical study titled "Phase 1 Study of OTS167 in Patients With Solid Tumors". The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in...
What is the current status of trial NCT01910545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-08-23. Estimated completion is 2016-05-04.
What interventions are being tested in trial NCT01910545?
The interventions under investigation include: OTS167IV (DRUG).
Who is sponsoring clinical trial NCT01910545?
This trial is sponsored by OncoTherapy Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.